Teleflex Names Medtronic Exec Jason Weidman as CEO

Teleflex has appointed Jason Weidman as president and CEO, effective June 8.

He will succeed Stuart Randle, who has been the company’s interim president and CEO since January and will continue as a member of the Teleflex board of directors.

Weidman boasts over 25 years of industry experience. He joins Teleflex from Medtronic, where he held a variety of senior leadership roles over almost 20 years, most recently as SVP and president of Coronary & Renal Denervation and SVP and president of Aortic, Peripheral and Venous.

“We’re thrilled to welcome Jason to Teleflex. Following the completion of the divestitures, Teleflex will be a fundamentally transformed company, with a portfolio focused on our core interventional, critical care and high acuity hospital markets,” said Dr. Stephen Klasko, Teleflex’s chairman of the board. “Jason’s medical technology expertise is closely aligned with our focused product portfolio, and his track record of driving growth, advancing product innovations and expanding global markets make him an ideal candidate to lead Teleflex’s go-forward strategy. With attractive, high-growth end markets, what will be a significantly enhanced capital structure from our intended $1 billion share buyback and $800 million debt paydown following the close of the sale transactions and an experienced and driven leadership team, we believe Teleflex will be an incredibly compelling growth story.”

Before Medtronic, Weidman help positions at Thoratec Corporation. He received an MBA in Health Care Management from the Wharton School at the University of Pennsylvania, an MS in Mechanical Engineering with a concentration in Biomechanics from Stanford University and a BSE in Mechanical Engineering from the University of Michigan.

“It’s an honor for me to join Teleflex at such an important inflection point and to help lead the Company into its next phase of growth,” said Weidman. “Having spent my entire career in the medical technology industry, I see a clear opportunity for Teleflex to build on its strong foundation and commitment to innovation, further shaping the future of healthcare while advancing our purpose of improving the health and quality of people’s lives.”

In December, the company revealed it entered agreements to sell its Acute Care, Interventional Urology, and OEM businesses to two buyers.